Astrotech Corporation reported a Q3 2024 period (calendar year 2024) characterized by a steep revenue decline on a sequential basis but a year-over-year growth signal that is driven by the company’s multi-segment exposure to technology development in aerospace, defense, and cannabis analytics. Revenue stood at $50,000 for the quarter, versus a heavy gross loss of $233,000 after cost of revenue of $283,000, resulting in a gross margin of -4.66%. The quarter featured an outsized research and development expense of $1.708 million, alongside selling, general and administrative costs of $1.592 million, driving a total operating expense of $3.30 million and an EBIT (loss) of -$3.533 million. Net income for the quarter was -$3.154 million, with basic/diluted earnings per share of -$1.93 on 1.633 million shares outstanding. EBITDA deteriorated to -$3.327 million, with an EBITDA margin of -66.54%. These dynamics reflect ongoing investment in next-generation platforms (ATI AMS technology, 1st Detect TRACER 1000, and AgLAB initiatives) and limited near-term top-line traction.